The Weight Management peptide category features some of the most clinically significant research compounds of the past decade. Semaglutide and Tirzepatide are GLP-1 (and dual GIP/GLP-1) receptor agonists that have revolutionized obesity and type 2 diabetes research, demonstrating substantial reductions in body weight, improved insulin sensitivity, and cardiovascular benefits in large-scale trials. Retatrutide (LY3437943) is a next-generation triple agonist (GIP/GLP-1/glucagon) currently under active clinical investigation. MOTS-C, a mitochondrial-derived peptide, offers a complementary angle — improving metabolic flexibility, insulin sensitivity, and exercise capacity.
This category is at the forefront of metabolic disease research, with applications spanning obesity, insulin resistance, NAFLD, and cardiovascular metabolic syndrome. All peptides are supplied as research-grade compounds for laboratory and preclinical use only.
Key peptides: Semaglutide, Tirzepatide, Retatrutide, MOTS-C, and more.